Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL22608699

N#Cc1ccc(-c2ccc(Sc3nn[nH]c3C(=O)O)cc2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ HAO1 Q9UJM8 12/20 0.41
▸ MAOA P21397 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ PTPN5 P54829 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ KIF11 P52732 1/20 0.35
▸ SLC22A12 Q96S37 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22816410 0.93 HAO1 (0.42) HAO1MAOAMAOB
SCHEMBL22608701 0.84 HAO1 (0.35) HAO1MAOAMAOBPTPN5HDAC1
SCHEMBL22807455 0.79 HAO1 (0.43) HAO1
Trifluoroacetic Acid SCHEMBL22608241 0.78 DPP4 (0.37) —
SCHEMBL22608306 0.78 RHEB (0.47) HAO1
SCHEMBL22608342 0.76 HAO1 (0.50) HAO1
SCHEMBL22608093 0.76 RHEB (0.41) HAO1
SCHEMBL22816408 0.76 L3MBTL1 (0.44) —
SCHEMBL21312391 0.76 MAOA (0.41) HAO1MAOAMAOBSLC22A12
Trifluoroacetic Acid SCHEMBL29490713 0.74 MEN1 (0.34) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 — — US disclosed
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 — — US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 — — US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 — — US disclosed
EP-3986863-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BioMarin Pharmaceutical Inc. (US) 2022-04-27 — — EP disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 — — US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 — — WO disclosed
EP-3732167-A2 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BioMarin Pharmaceutical Inc. (US) 2020-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 9/4885MAOA 91/4885MAOB 68/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 10/4885MAOA 107/4885MAOB 78/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT HAO1 9/4885MAOA 91/4885MAOB 68/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 9/4885MAOA 91/4885MAOB 68/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 9/4885MAOA 91/4885MAOB 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback